Allergan’s Botox misses the bullseye in PhII depression study, but researchers confident they can hit it in a major PhIII
Allergan’s sizable Phase II study testing Botox as a treatment for major depression among women missed hitting statistical significance for the primary endpoint at six weeks of therapy. But it didn’t miss by much, and the low dose did score at a couple of other time points in the study, giving Allergan $AGN execs enough confidence to move the therapy into a major Phase III program.
Researchers put two doses of Botox — 30 units and 50 units — into the study, which recruited 258 patients. The 50-unit dose was a bust. But:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.